GeneReach Biotechnology Corp. (4171.TWO)
TWD 27.15
(1.69%)
TWD 27.15
(1.69%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -38.67 Million | 357.63 Million | 348.98 Million | 169.81 Million | - |
| Net Income | -218.34 Million | 272.37 Million | 469.37 Million | 338.94 Million | - |
| Depreciation & Amortization | 68.88 Million | 65.16 Million | 60 Million | 51.83 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | 99.55 Million | 135.87 Million | -110.89 Million | -204.94 Million | - |
| Other non-cash items | -8.71 Million | 3.04 Million | 5.21 Million | 2.54 Million | - |
| Investing Cash Flow | -249.91 Million | -48.01 Million | -41.7 Million | -108.9 Million | - |
| Investments in PPE | -27.35 Million | -50.46 Million | -15.78 Million | -64.87 Million | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | -263.04 Million | - | -31.54 Million | - | - |
| Sales/Maturities of investments | 41.5 Million | - | -26.41 Million | -42.72 Million | - |
| Other Investing Activities | -1.01 Million | -1.47 Million | 3.65 Million | -2.12 Million | - |
| Financing Cash Flow | -215.88 Million | -228.28 Million | 43.47 Million | 75.05 Million | - |
| Debt repayment | -135 Million | -7.5 Million | -196 Million | -81 Million | - |
| Dividends payments | -68.94 Million | -208.93 Million | -143.67 Million | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - |
| Other Financing Activities | -11.93 Million | - | -37 Thousand | - | - |
| Accounts receivables | 13.36 Million | - | - | - | - |
| Accounts payables | -239 Thousand | - | - | - | - |
| Inventory | 124.58 Million | 16.06 Million | -91.28 Million | -156.1 Million | - |
| Other working capital | -38.39 Million | - | - | - | - |
| Cash at beginning of period | 748.61 Million | 663.43 Million | 313.68 Million | 177.01 Million | - |
| Cash at end of period | 216.77 Million | 748.61 Million | 663.43 Million | 313.68 Million | - |
| Capital Expenditure | -27.35 Million | -50.46 Million | -15.78 Million | -64.87 Million | - |
| Effect of forex changes on cash | -27.37 Million | 3.84 Million | -1 Million | 689 Thousand | - |
| Net cash flow / Change in cash | -531.84 Million | 85.18 Million | 349.75 Million | 136.66 Million | - |
| Free Cash Flow | -66.02 Million | 307.17 Million | 333.2 Million | 104.94 Million | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -37.24 Million | -21.52 Million | -107.24 Million | -218.34 Million | -25.87 Million | -47.15 Million |
| Depreciation & Amortization | 19.07 Million | 18.84 Million | 17.98 Million | 68.88 Million | 17.49 Million | 16.73 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -4.9 Million | 7.46 Million | 56.06 Million | 99.55 Million | 16.21 Million | 49.96 Million |
| Other non-cash items | -4.52 Million | -1.68 Million | -2.76 Million | -8.71 Million | -3.73 Million | -3.52 Million |
| Investing Cash Flow | -37.07 Million | 15.73 Million | -265.01 Million | -249.91 Million | 312.68 Million | -290.49 Million |
| Investments in PPE | -3.32 Million | -2.18 Million | -5.33 Million | -27.35 Million | -5.72 Million | -8.55 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -45.09 Million | - | -259.8 Million | -263.04 Million | 277.02 Million | 85.14 Million |
| Sales/Maturities of investments | 12.55 Million | 17.78 Million | - | 41.5 Million | 41.5 Million | - |
| Other Investing Activities | -1.19 Million | 133 Thousand | 124 Thousand | -1.01 Million | -107 Thousand | -1.67 Million |
| Financing Cash Flow | 36.87 Million | 36.01 Million | 35.15 Million | -215.88 Million | -241.27 Million | -4.72 Million |
| Debt repayment | -40 Million | -39 Million | -38.12 Million | -135 Million | -169.37 Million | -1.87 Million |
| Dividends payments | - | - | - | -68.94 Million | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 40 Million | - | - | - | - | - |
| Accounts receivables | -4.36 Million | - | - | - | - | - |
| Accounts payables | -224 Thousand | - | - | - | - | - |
| Inventory | -768 Thousand | 8.57 Million | 53.69 Million | 124.58 Million | 10.17 Million | 34.71 Million |
| Other working capital | -1.2 Million | - | - | - | - | - |
| Cash at beginning of period | 270.16 Million | 216.77 Million | 494.21 Million | 748.61 Million | 409.89 Million | 691.52 Million |
| Cash at end of period | 246.85 Million | 270.16 Million | 216.77 Million | 216.77 Million | 494.21 Million | 409.89 Million |
| Capital Expenditure | -3.32 Million | -2.18 Million | -5.33 Million | -27.35 Million | -5.72 Million | -8.55 Million |
| Effect of forex changes on cash | -15.79 Million | 2.09 Million | -27.82 Million | -27.37 Million | 2.09 Million | -1.85 Million |
| Net cash flow / Change in cash | -23.3 Million | 53.38 Million | -277.44 Million | -531.84 Million | 84.32 Million | -281.63 Million |
| Free Cash Flow | -10.63 Million | -2.64 Million | -25.09 Million | -66.02 Million | 5.09 Million | 6.88 Million |
CTPL5
FRCOY
PHSC
AMPE
7388
COTY